Zenas BioPharma, Inc. (ZBIO) — Stock Score Summary

Zenas BioPharma, Inc. (ZBIO) has a MoatMap StockRank of 2/100 based on Quality (21/100), Value (31/100), and Momentum (21/100) factor scores. The current signal is STRONG SELL. Zenas BioPharma is a clinical-stage biopharmaceutical company. It does not possess the established manufacturing assets or regulatory moats of a high-utilization CDMO, making it too speculative for our concentrated portfolio.

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative immunology- and inflammation-focused therapies. The company's competitive moat is centered on its proprietary pipeline of bifunctional antibodies, led by its candidate obexelimab, which targets autoimmune diseases through a novel mechanism of action. It operates as an early-stage biotechnology innovator aiming to address significant unmet medical needs in global immunology markets.

Key Financial Metrics

Price$18.42
Market Cap$1.2B
P/E (Forward)-8.11
Return on Equity-137.1%
Return on Invested Capital-115.4%
Debt/Equity79.45
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-166M

Zenas BioPharma, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Zenas BioPharma, Inc.’s (ZBIO) StockRank?
MoatMap’s StockRank for Zenas BioPharma, Inc. (ZBIO) is 2/100, with a Strong Sell signal. It is a composite of Quality (21), Value (31), and Momentum (21) factor ranks across MoatMap’s 19,000+ stock universe.
Does Zenas BioPharma, Inc. have an economic moat?
Zenas BioPharma, Inc. (ZBIO) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Zenas BioPharma, Inc. a buy, hold, or sell?
MoatMap’s current signal for Zenas BioPharma, Inc. (ZBIO) is Strong Sell, based on a StockRank of 2/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Zenas BioPharma, Inc. in?
Zenas BioPharma, Inc. (ZBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksZBIO deep dive reportAI ChampionsHow we score stocksSense-check another stock